Tesaro’s PARP ovarian cancer drug (niraparib) hits PhIII goal; prepares to file Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Wednesday, June 29, 2016

Tesaro’s PARP ovarian cancer drug (niraparib) hits PhIII goal; prepares to file



financial biotech news

 The Waltham, MA-based biotech said its Phase III trial for niraparib hit its primary endpoint of progression-free survival (PFS) against placebo across several sets of patients--including those who were positive for germline BRCA mutation, and another set that do not carry this mutation--as well as those who have homologous recombination deficient (HRD) tumors as determined by a diagnostic kit.

0 comments :

Post a Comment

Your comments?